Population Pharmacokinetics and Safety of Oral Tetra-Arsenic Tetra-Sulfide Formula in Pediatric Acute Promyelocytic Leukemia.

Li ZhangXin-Mei YangJing ChenLei HuFan YangYue ZhouBei-Bei ZhaoWei ZhaoXiao-Fan Zhu

Published in: Drug design, development and therapy (2021)

The pharmacokinetics and safety oral AS4S4 formula was evaluated for the first time in pediatric APL. The pharmacokinetic assessment demonstrated that the dosing regimen of 60 mg/kg/d TID resulted in a higher steady-state through concentration in children than that which was achieved in adults. The results of this study indicate that the AS4S4 formula is safe in newly diagnosed pediatric APL patients.

Keyphrases

newly diagnosed
end stage renal disease
human milk
ejection fraction
chronic kidney disease
liver failure
acute myeloid leukemia
peritoneal dialysis
young adults
drinking water
risk assessment
low birth weight
drug induced
acute respiratory distress syndrome
aortic dissection